News from actavis, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 09, 2014, 17:10 ET
Actavis plc logo. (PRNewsFoto/Actavis plc)

FDA Advisory Committee Recommends Against Approval of Actavis' Nebivolol/Valsartan Fixed-Dose Combination NDA for Treatment of Hypertension

 Actavis plc (NYSE: ACT) today confirmed that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee...

Sep 05, 2014, 08:00 ET
Actavis plc logo. (PRNewsFoto/Actavis plc)

Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product

 Actavis plc (NYSE: ACT) today confirmed that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' application for...

Sep 02, 2014, 09:20 ET
Actavis plc logo. (PRNewsFoto/Actavis plc)

Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline

Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' New Drug Application...

Aug 26, 2014, 16:05 ET
Actavis plc logo. (PRNewsFoto/Actavis plc)

Actavis to Present at Morgan Stanley Global Healthcare Conference 2014

 Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Brenton Saunders, CEO and President of...

Aug 22, 2014, 16:05 ET
Actavis plc logo. (PRNewsFoto/Actavis plc)

Actavis Confirms Generic Neupro® Patent Challenge

 Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug...

Aug 19, 2014, 07:24 ET
Actavis plc logo. (PRNewsFoto/Actavis plc)

Actavis Announces Positive Topline Results From The Phase III Program Of Ceftazidime-Avibactam In Patients With Complicated Intra-Abdominal Infections(cIAI)

 Actavis plc (NYSE: ACT) today confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the potential for...

Aug 05, 2014, 07:00 ET
Actavis plc logo. (PRNewsFoto/Actavis plc)

Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42

 Actavis plc (NYSE: ACT) today reported net revenue increased 34 percent to $2.67 billion for the second quarter ended June 30, 2014, compared...

Jul 21, 2014, 16:30 ET
Actavis plc logo. (PRNewsFoto/Actavis plc)

Medicines360 and Actavis Announce FDA Acceptance for Filing of NDA for Levosert™ IUD

Medicines360, a non-profit women's health pharmaceutical company, and Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company,...

Jul 11, 2014, 16:25 ET
Actavis plc logo. (PRNewsFoto/Actavis plc)

Actavis Confirms Generic Diclegis® Patent Challenge

 Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug...

Jul 08, 2014, 16:05 ET
Actavis plc logo. (PRNewsFoto/Actavis plc)

Actavis Confirms Generic Ampyra® Patent Challenge

 Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug...

Jul 02, 2014, 08:46 ET
Actavis plc logo. (PRNewsFoto/Actavis plc)

Actavis Completes Acquisition of Furiex Pharmaceuticals

Actavis plc (NYSE: ACT) today announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex...

Jul 02, 2014, 08:00 ET
http://photos.prnewswire.com/prnvar/20130124/NY47381LOGO

Actavis Announces Final Stockholder Merger Consideration Election Results in Connection with Forest Laboratories Acquisition

 Actavis plc (NYSE: ACT) today announced the final results of the elections made by stockholders of Forest Laboratories, Inc. ("Forest")...

Jul 01, 2014, 09:00 ET
Actavis plc logo. (PRNewsFoto/Actavis plc)

Actavis plc Appoints New Members and Announces Changes to Board of Directors Following Close of Forest Laboratories, Inc. Acquisition

Actavis plc (NYSE: ACT) today announced the appointment of three new members to the Company's Board of Directors, including Actavis' newly...

Jul 01, 2014, 08:30 ET
Actavis plc logo. (PRNewsFoto/Actavis plc)

Actavis Completes Forest Laboratories Acquisition

 Actavis plc (NYSE: ACT) today announced that it has completed the acquisition of Forest Laboratories, Inc. (NYSE: FRX) in a cash and equity...

Jul 01, 2014, 08:20 ET
Actavis plc logo. (PRNewsFoto/Actavis plc)

Actavis Completes Forest Laboratories Acquisition

 Actavis plc (NYSE: ACT) today announced that it has completed the acquisition of Forest Laboratories, Inc. (NYSE: FRX) in a cash and equity...

Jun 30, 2014, 17:15 ET
Actavis plc logo. (PRNewsFoto/Actavis plc)

Actavis and Forest Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Forest

 Actavis plc (NYSE: ACT) and Forest Laboratories, Inc. (NYSE: FRX) today announced that the U.S. Federal Trade Commission (FTC) has voted to...

Jun 30, 2014, 08:30 ET
Actavis plc logo. (PRNewsFoto/Actavis plc)

Actavis and Forest Announce Preliminary Stockholder Merger Consideration Election Results

 Actavis plc (NYSE: ACT) and Forest Laboratories, Inc. (NYSE: FRX) today announced the preliminary results of the elections made by...

Jun 30, 2014, 08:00 ET
Actavis plc logo. (PRNewsFoto/Actavis plc)

Actavis to Host Second Quarter 2014 Earnings Conference Call and Webcast

 Actavis plc (NYSE: ACT) today announced that it intends to release second quarter 2014 financial results on Tuesday, August 5, 2014, prior to...

Jun 30, 2014, 07:30 ET
Actavis plc logo. (PRNewsFoto/Actavis plc)

Actavis Confirms Generic Zubsolv® Patent Challenge

Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration...

Jun 26, 2014, 07:00 ET

Lowest Dose Oral Contraceptive for Preventing Pregnancy -- LOLO™ -- Now Available in Canada

OAKVILLE, ON, June 26, 2014 /CNW/ - As scientific evidence has accumulated, there has been a movement toward lower dose estrogen formulations of...